An open-label, two-period, randomized, crossover study to evaluate the effect of food on the pharmacokinetics of single doses of pazopanib in cancer patients

Trial Profile

An open-label, two-period, randomized, crossover study to evaluate the effect of food on the pharmacokinetics of single doses of pazopanib in cancer patients

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2011

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 03 Aug 2011 Results published in the Investigational New Drugs.
    • 24 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top